These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 28851085)

  • 1. The effect of APOE, CETP, and PCSK9 polymorphisms on simvastatin response in Thai hypercholesterolemic patients.
    Wanmasae S; Sirintronsopon W; Porntadavity S; Jeenduang N
    Cardiovasc Ther; 2017 Dec; 35(6):. PubMed ID: 28851085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of APOE and CETP TaqIB Polymorphisms with Type 2 Diabetes Mellitus.
    Srirojnopkun C; Kietrungwilaikul K; Boonsong K; Thongpoonkaew J; Jeenduang N
    Arch Med Res; 2018 Oct; 49(7):479-485. PubMed ID: 30853126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined PCSK9 and APOE polymorphisms are genetic risk factors associated with elevated plasma lipid levels in a Thai population.
    Jeenduang N; Porntadavity S; Wanmasae S
    Lipids; 2015 Jun; 50(6):543-53. PubMed ID: 25899039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. APOE and CETP TaqIB polymorphisms influence metabolic responses to Hibiscus sabdariffa L. and Gynostemma pentaphyllum Makino tea consumption in hypercholesterolemic subjects.
    Jeenduang N; Sangkaew B; Chantaracha P; Chanchareonsri S; Plyduang T; Thitdee W; Samae C; Pitumanon W
    Asia Pac J Clin Nutr; 2017 Mar; 26(2):368-378. PubMed ID: 28244718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetic study of apolipoprotein E, cholesteryl ester transfer protein and hepatic lipase genes and simvastatin therapy in Brazilian subjects.
    Fiegenbaum M; da Silveira FR; Van der Sand CR; Van der Sand LC; Ferreira ME; Pires RC; Hutz MH
    Clin Chim Acta; 2005 Dec; 362(1-2):182-8. PubMed ID: 16038892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of PCSK9 polymorphisms on plasma lipids and response to atorvastatin treatment in Brazilian subjects.
    Anderson JM; Cerda A; Hirata MH; Rodrigues AC; Dorea EL; Bernik MM; Bertolami MC; Faludi AA; Hirata RD
    J Clin Lipidol; 2014; 8(3):256-64. PubMed ID: 24793346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between the cholesterol ester transfer protein TaqIB polymorphism and the lipid-lowering effect of atorvastatin in patients with coronary atherosclerotic heart disease.
    Li J; Zhang L; Xie NZ; Deng B; Lv LX; Zheng LQ
    Genet Mol Res; 2014 Mar; 13(1):2140-8. PubMed ID: 24737438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of PCSK9 variants on common carotid artery intima media thickness and relation to ApoE alleles.
    Norata GD; Garlaschelli K; Grigore L; Raselli S; Tramontana S; Meneghetti F; Artali R; Noto D; Cefalù AB; Buccianti G; Averna M; Catapano AL
    Atherosclerosis; 2010 Jan; 208(1):177-82. PubMed ID: 19619878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cholesteryl ester transfer protein and ATP-binding cassette transporter A1 genotype alter the atorvastatin and simvastatin efficacy: time for genotype-guided therapy?
    Kolovou G; Kolovou V; Mihas C; Giannakopoulou V; Vasiliadis I; Boussoula E; Kollia A; Boutsikou M; Katsiki N; Mavrogeni S
    Angiology; 2013 May; 64(4):266-72. PubMed ID: 22584245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of association between SLCO1B1 polymorphisms and lipid-lowering response to simvastatin therapy in Thai hypercholesterolaemic patients.
    Kaewboonlert N; Thitisopee W; Sirintronsopon W; Porntadavity S; Jeenduang N
    J Clin Pharm Ther; 2018 Oct; 43(5):647-655. PubMed ID: 29575099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies of the CETP TaqIB and ApoE Polymorphisms in Southern Thai Subjects with the Metabolic Syndrome.
    Jeenduang N; Porntadavity S; Nuinoon M; Horpet D; Thepkwan N; Thaworn P; Theanmontri S
    Biochem Genet; 2015 Aug; 53(7-8):184-99. PubMed ID: 26014924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proprotein convertase subtilisin/kexin type 9 gene E670G polymorphism interacts with alcohol consumption to modulate serum lipid levels.
    Aung LH; Yin RX; Wu DF; Cao XL; Hu XJ; Miao L
    Int J Med Sci; 2013; 10(2):124-32. PubMed ID: 23329883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetic study of cholesteryl ester transfer protein gene and simvastatin treatment in hypercholesterolaemic subjects.
    Anagnostopoulou K; Kolovou G; Kostakou P; Mihas C; Mikhailidis D; Cokkinos DV
    Expert Opin Pharmacother; 2007 Oct; 8(15):2459-63. PubMed ID: 17931083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of HMG-CoA reductase inhibitor on plasma cholesteryl ester transfer protein activity in primary hypercholesterolemia: comparison among CETP/TaqIB genotype subgroups.
    Kotake H; Sekikawa A; Tokita Y; Ishigaki Y; Oikawa S
    J Atheroscler Thromb; 2002; 9(5):207-12. PubMed ID: 12409629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating PCSK9 levels and CETP plasma activity are independently associated in patients with metabolic diseases.
    Girona J; Ibarretxe D; Plana N; Guaita-Esteruelas S; Amigo N; Heras M; Masana L
    Cardiovasc Diabetol; 2016 Aug; 15(1):107. PubMed ID: 27488210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lunasin Improves the LDL-C Lowering Efficacy of Simvastatin via Inhibiting PCSK9 Expression in Hepatocytes and ApoE
    Gu L; Gong Y; Zhao C; Wang Y; Tian Q; Lei G; Liang Y; Zhao W; Tan S
    Molecules; 2019 Nov; 24(22):. PubMed ID: 31731717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of genetic variants related to lipid metabolism as risk factors for cholelithiasis after bariatric surgery in Brazilian population.
    Pinheiro-Júnior S; Pinhel MA; Nakazone MA; Pinheiro A; Amorim GF; Florim GM; Mazeti CM; Gregório ML; Moschetta MG; Brito GB; Brienze SL; Nonino CB; Brandão AC; Souza DR
    Obes Surg; 2012 Apr; 22(4):623-33. PubMed ID: 22271356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proprotein convertase substilisin/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates.
    Liang H; Chaparro-Riggers J; Strop P; Geng T; Sutton JE; Tsai D; Bai L; Abdiche Y; Dilley J; Yu J; Wu S; Chin SM; Lee NA; Rossi A; Lin JC; Rajpal A; Pons J; Shelton DL
    J Pharmacol Exp Ther; 2012 Feb; 340(2):228-36. PubMed ID: 22019884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regional distribution and metabolic effect of PCSK9 insLEU and R46L gene mutations and apoE genotype.
    Awan Z; Delvin EE; Levy E; Genest J; Davignon J; Seidah NG; Baass A
    Can J Cardiol; 2013 Aug; 29(8):927-33. PubMed ID: 23743349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial.
    Desai NR; Kohli P; Giugliano RP; O'Donoghue ML; Somaratne R; Zhou J; Hoffman EB; Huang F; Rogers WJ; Wasserman SM; Scott R; Sabatine MS
    Circulation; 2013 Aug; 128(9):962-9. PubMed ID: 23884353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.